12:00 AM
 | 
Apr 18, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Tysabri natalizumab regulatory update

FDA updated the label of Tysabri natalizumab from Biogen Idec and Elan to include incidence rates of progressive multifocal leukoencephalopathy (PML) by duration of therapy. The partners market the humanized...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >